HRTX - Why Is Pain Treatment Focused Heron Therapeutics Stock Trading Higher Today? | Benzinga
Heron Therapeutics Inc (NASDAQ: HRTX) reported Q3 sales of $31.43 million, missing the consensus of $32.75 million.
The company reported a Q3 EPS loss of $(0.17), lower than $(0.38) a year, and beating the consensus of $(0.29).
The company implemented a cost reduction plan to decrease operating expenses by 26% in 2023 compared to 2022, and full-year 2024 operating expenses to be around $108 million-$116 million.
The company sees FY23 sales of $123 million-$125 million compared to a prior range ...